The association between the Serine/threonine kinase 15 (STK15) F31I polymorphism (rs2273535) and cancer susceptibility remains controversial. To further investigate this potential relationship, we conducted a comprehensive meta-analysis of 27 published studies involving a total of 19,267 multiple cancer cases and 24,359 controls. Our results indicate statistical evidence of an association between the STK15 F31I polymorphism and the increased risk of overall cancer in four genetic models: AA vs. TA+TT, AA vs. TT, AA vs. TA, and A vs. T. In a stratified analysis by cancer type, there was an increased risk of breast cancer in four genetic models: AA vs. TA+TT, AA vs. TT, AA vs. TA, and A vs. T, as well as esophageal cancer in two genetic models: AA vs. TA+TT and AA vs. TA. In a stratified analysis by ethnicity, there was a significant increase in cancer risk among Asians, but not Caucasians, in four genetic models: AA vs. TA+TT, AA vs. TT, AA vs. TA and A vs. T. In addition, a stratified analysis by ethnicity in the breast cancer subgroup revealed a significant increase in cancer risk among Asians in two genetic models: AA vs. TA+TT and AA vs. TT, as well as among Caucasians in one genetic model: AA vs. TA. In summary, this meta-analysis demonstrates that the STK15 F31I polymorphism may be a risk factor for cancer.
Citation: Tang W, Qiu H, Ding H, Sun B, Wang L, Yin J, et al. (2013) Association between the STK15 F31I Polymorphism and Cancer Susceptibility: A Meta-Analysis Involving 43,626 Subjects. PLoS ONE 8(12): e82790. https://doi.org/10.1371/journal.pone.0082790
Editor: Hiromu Suzuki, Sapporo Medical University, Japan
Received: July 31, 2013; Accepted: October 28, 2013; Published: December 13, 2013
Copyright: © 2013 Tang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by Jiangsu University Clinical medicine science and technology development fund (JLY20120004). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Cancer is a complex disease that results from interactions between multiple genetic and environmental factors [1-3]. A characteristic of cancer is genetic instability, which can be caused by transgenation and acquired aneuploidy . Genetic instability mostly occurs at the chromosomal level, including losses and gains of whole or large portions of chromosomes . Chromosomal segregation is accomplished by the mitotic spindle, which links whole chromosomes to opposite poles of the cell, and segregates the duplicated DNA equally into two daughter cells . In mammalian cells, centrosomes are the major microtubule organizing centers (MTOC) and play a vital role in symmetrical mitotic spindle formation and mitosis. Serine/threonine kinase 15 (STK15), a centrosome-localized serine/threonine kinase, acts as a critical regulator of mitotic centrosome maturation and spindle assembly. It has a particular role in G2 to M phase, primarily through its phosphorylation functions, and plays an important role in the development and progression of cancer malignancy .
A non-synonymous single nucleotide polymorphism (SNP) of STK15, the F31I polymorphism (rs2273535), has been identified in the coding region of STK15. The STK15 F31I polymorphism (91 T→A), a SNP in exon 3 of STK15, encodes a phenylalanine→isoleucine substitution at amino acid residue 31 (F31I) . In recent years, the F31I polymorphism has been intensely investigated for its association with the risk of multiple cancers. Many studies have indicated that the STK15 F31I polymorphism is a general low penetrance susceptibility gene in a number of cancers, particularly breast, colorectal, and esophageal cancer [9-11]. However, results from these studies remain inconsistent, perhaps due to small sample size limitations, ethnic diversity in allele frequencies, and publication bias. Therefore, to confirm the role of the STK15 F31I polymorphism in tumorigenesis, we conducted a comprehensive meta-analysis on eligible case-control studies published to date. To the best of our knowledge, this is the most comprehensive meta-analysis regarding the STK15 F31I polymorphism and its association with cancer risk.
Materials and Methods
Genetic association articles published on cancer and the STK15 F31I polymorphism, up to May 29, 2013, were investigated by searching PubMed, EMBASE, CBM (Chinese BioMedical Disc) and CNKI (Chinese National Knowledge Infrastructure) with combinations of the following terms: "stk15", "Aurora-A", "BTAK", "AIKI", "polymorphism", "SNP", "mutation", "carcinoma", "cancer", "neoplasm", and "malignance". In addition, the publication language was restricted to English and Chinese. All bibliographies listed in these studies and published reviews were checked for original and relevant studies.
Inclusion and Exclusion Criteria
Eligible studies had to meet the following criteria: 1) evaluated the STK15 F31I polymorphism and cancer risk, 2) designed as a case-control study, 3) provided data on genotype or allele frequency in case groups and control groups, 4) provided the genotyping method and ethnicity, and 5) control genotype distributions consistent with Hardy-Weinberg equilibrium (HWE). Exclusion criteria included the following: 1) overlapping data, 2) not case-control studies, and 3) review publication.
Information from all eligible publications was carefully and independently extracted through three reviewers (W. Tang, H. Qiu, and H. Ding). In case of conflicting evaluations, differences were resolved by further discussion among all reviewers. For each included study the following data was extracted: first author, cancer type, year of publication, country, ethnicity of study subjects, number of cases and controls, genotype method, allele and genotype frequency, and HWE in controls.
Deviation from the HWE among the controls was evaluated for each single study using an internet-based HWE calculator (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl). The crude odds ratio (OR) with the corresponding 95% confidence intervals (95% CI) was used to measure the strength of the association between the STK15 F31I polymorphism and cancer risk. The significance of the pooled OR was assessed using the Z-test and P-value (two-tailed), and P<0.05 was considered statistically significant. In our study, a Chi-square-based I2 test was used to check potential heterogeneity among studies; I2<25% indicated low heterogeneity, 25%≤I2≤50% indicated moderate heterogeneity, and I2>50% indicated large heterogeneity . The heterogeneity was considered statistically significant at I2>50% or P<0.10. If heterogeneity existed, the pooled ORs were calculated according to the random-effects model (the DerSimonian–Laird method) or the fixed-effects model was used (the Mantel–Haenszel method). Subgroup analyses were conducted according to ethnicity and cancer type to measure ethnicity-specific and cancer type-specific effects (any cancer type evaluated by less than three individual case-control studies was combined into "other cancers"). Sensitivity analysis was also carried out to determine whether any excluded studies affected the stability of our results. Galbraith radial plot and further stratified analyses were used to analyze the source the heterogeneity. In our studies, the funnel plot and Egger’s test were used to assess potential publication bias, which was measured by visual inspection of an asymmetric plot. In addition, for the interpretation of Egger’s test, statistical significance was defined as P<0.05. Statistical analyses were performed using STATA (v12.0) statistical software.
After an initial search, a total of 151 published articles relevant to the topic were identified from databases (PubMed, Embase, CBM and CNKI). With additional filters, 120 of these articles were excluded (26 for duplication of titles, 10 for not being case-control studies, five for an association with cancer treatment, 72 for irrelevance to gene polymorphisms and cancer, six reviews and one case-control study for overlapping data). After this step, 31 qualified and original papers fit the inclusion criteria. After a manual search of the bibliography lists from retrieved articles, another two articles were included (Figure 1). Afterwards, six case-control studies were excluded because the number of genotypes in the control group statistically deviated from HWE. Overall, 27 total case-control studies on the association between the STK15 F31I polymorphism and cancer risk were recruited in this meta-analysis. Among the 27 case-control studies, ten investigated breast cancer [8,9,14-21], four investigated colorectal cancer [10,22-24], and three investigated esophageal cancer [11,25,26]. The other studies investigated gastric cancer, lung cancer, renal cell carcinoma, bladder cancer, glioblastoma, hepatocellular carcinoma, and ovarian cancer [27-36]. As for subjects in these studies, 11 were Asian [9,11,19-21,23,25-29] and 16 were Caucasian [8,10,14-18,22,24,30-36]. Characteristics of populations and cancer types in each individual study recruited in the meta-analysis are listed in Table 1. The distribution of the STK15 F31I polymorphism and allele among patients and controls is listed in Table 2. Results of the meta-analysis from different comparative genetic models are summarized in Table 3, Table 4, and Table 5.
|Study||Year||Ethnicity||Country||Cancer type||Sample size (case/control)||Genotype method|
|Sang et al.||2012||Asians||China||esopheal cancer||380/380||MALDI-TOF MS|
|Ruan et al.||2011||Asians||China||breast cancer||1334/1568||TaqMan|
|Navaratne et al.||2010||Caucasians||USA||glioblastoma||96/93||PCR-RFLP|
|Akkiz et al.||2010||Caucasians||Turkey||hepatocellular carcinoma||128/128||PCR-RFLP|
|Song et al.||2010||Asians||China||bladder cancer||60/60||PCR-RFLP|
|Chen et al.||2009||Asians||China||esopheal cancer||188/324||PCR-RFLP|
|MARIE-GENICA||2009||Caucasians||German||breast cancer||3136/5466||MALDI-TOF MS|
|Ricketts et al.||2009||Caucasians||Polish||renal cell carcinoma||328/311||MLPA|
|Dogan et al.||2008||Caucasians||Turkey||lung Cancer||102/102||Direct sequencing|
|Chen et al.||2007||Caucasians||USA||colorectal cancer||60/65||Direct sequencing|
|Wang et al.||2007||Caucasians||USA||lung cancer||1518/1518||TaqMan|
|Vidarsdottir et al.||2007||Caucasians||Iceland||breast cancer||759/653||TaqMan|
|Tchatchou et al.||2007||Caucasians||German||breast cancer||727/819||TaqMan|
|Hammerschmied et al.||2007||Caucasians||German;USA||renal cell carcinoma||156/158||PCR-RFLP|
|Webb et al.||2006||Caucasians||UK||colorectal cancer||2558/2680||Illuminasentric bead array|
|Fletcher et al.||2006||Caucasians||UK||breast cancer||507/875||PCR-RFLP|
|Zhang et al.||2006||Asians||China||colorectal cancer||283/283||PCR-RFLP|
|Cox. et al.||2006||Caucasians||USA||breast cancer||1259/1742||TaqMan|
|Ju et al.||2006||Asians||Korea||gastric cancer||501/427||MALDI-TOF MS|
|Chen et al.||2005||Asians||China||gastric cancer||68/75||PCR-RFLP|
|Hienonen et al.||2005||Caucasians||Finland||colorectal cancer||235/94||Direct sequencing|
|Lo et al.||2005||Asians||China(Taiwan)||breast cancer||709/1972||TaqMan|
|DiCioccio et al.||2004||Caucasians||UK;Denmark;USA||ovarian Cancer||1821/2467||TaqMan|
|Sun et al.||2004||Asians||China||breast cancer||520/520||PCR-RFLP|
|Egan et al.||2004||Caucasians||USA||breast cancer||940/830||Direct sequencing|
|Miao et al.||2004||Asians||China||esopheal cancer||656/656||PCR-RFLP|
|Dai et al.||2004||Asians||China||breast cancer||1193/1310||TaqMan|
|Sang et al.||46||161||173||39||188||153||253||507||266||494||Yes|
|Ruan et al.||167||568||599||161||691||716||902||1766||1013||2123||Yes|
|Navaratne et al.||4||33||59||6||33||54||41||151||45||141||Yes|
|Akkiz et al.||4||47||77||2||27||99||55||201||31||225||Yes|
|Song et al.||33||15||12||18||25||17||81||39||61||59||Yes|
|Chen et al.||66||79||43||118||168||38||211||165||404||244||Yes|
|Ricketts et al.||207||105||16||171||122||18||519||137||464||158||Yes|
|Dogan et al.||6||38||58||3||40||59||50||154||46||158||Yes|
|Chen et al.||3||13||44||6||21||38||19||101||33||97||Yes|
|Wang et al.||36||373||692||51||320||594||445||1757||422||1508||Yes|
|Vidarsdottir et al.||42||288||429||21||231||401||372||1146||273||1033||Yes|
|Tchatchou et al.||433||257||37||485||287||47||1123||331||1257||381||Yes|
|Hammerschmied et al.||7||57||92||12||65||81||71||241||89||227||Yes|
|Webb et al.||114||880||1564||125||888||1667||1108||4008||1138||4222||Yes|
|Fletcher et al.||18||154||335||48||280||547||190||824||376||1374||Yes|
|Zhang et al.||142||111||30||104||137||42||395||171||345||221||Yes|
|Cox. et al.||66||401||774||65||571||1075||533||1949||701||2721||Yes|
|Ju et al.||211||215||75||179||190||58||637||365||548||306||Yes|
|Chen et al.||36||27||5||33||32||10||99||37||98||52||Yes|
|Hienonen et al.||19||94||122||5||43||46||132||338||53||135||Yes|
|Lo et al.||348||288||71||886||887||196||984||430||2659||1279||Yes|
|DiCioccio et al.||71||502||821||99||649||1213||644||2144||847||3075||Yes|
|Sun et al.||256||214||50||192||262||66||726||314||646||394||Yes|
|Egan et al.||50||331||559||31||283||516||431||1449||345||1315||Yes|
|Miao et al.||308||290||58||249||316||91||906||406||814||498||Yes|
|Dai et al.||490||491||121||534||503||149||1471||733||1571||801||Yes|
|Polymorphism||Genetic comparison||Population||OR(95%CI)||P||Test of heterogeneity||Model|
|AA+TA vs. TT||All||1.04(0.97-1.12)||0.265||0.002||50.1%||R|
|AA vs. TA+TT||All||1.18(1.06-1.31)||0.002||0.000||56.2%||R|
|AA vs. TT||All||1.16(1.01-1.32)||0.035||0.000||55.7%||R|
|TA vs. TT||All||1.01(0.95-1.08)||0.745||0.028||37.2%||R|
|AA vs. TA||All||1.18(1.06-1.30)||0.001||0.003||48.4%||R|
|A vs. T||All||1.08(1.01-1.14)||0.015||0.000||64.4%||R|
|Polymorphism||Genetic comparison||Cancer type||OR(95%CI)||P||Test of heterogeneity||Model|
|AA+TA vs. TT||All||1.04(0.97-1.12)||0.265||0.002,||50.1%||R|
|AA vs. TA+TT||All||1.18(1.06-1.31)||0.002||0.000||56.2%||R|
|AA vs. TT||All||1.16(1.01-1.32)||0.035||0.000||55.7%||R|
|STK15 F31I||Esophageal cancer||1.02(0.47-2.22)||0.963||0.000||88.6%||R|
|TA vs. TT||All||1.01(0.95-1.08)||0.745||0.028||37.2%||R|
|AA vs. TA||All||1.18(1.06-1.30)||0.001||0.003||48.4%||R|
|A vs. T||All||1.08(1.01-1.14)||0.015||0.000||64.4%||R|
|Polymorphism||Genetic comparison||Population||OR(95%CI)||P||Test of heterogeneity||Model|
|AA+TA vs. TT||All||1.05(0.99-1.10)||0.120||0.462||0.0%||F|
|AA vs. TA+TT||All||1.20(1.05-1.37)||0.007||0.005||61.5%||R|
|AA vs. TT||All||1.22(1.10-1.35)||0.000||0.131||34.6%||F|
|TA vs. TT||All||1.01(0.96-1.07)||0.667||0.752||0.0%||F|
|AA vs. TA||All||1.19(1.04-1.36)||0.011||0.011||57.8%||R|
|A vs. T||All||1.08(1.01-1.15)||0.017||0.025||52.8%||R|
In total, 19,267 multiple cancer cases and 24,359 controls from 27 eligible and original case–control studies were recruited for meta-analysis of the association between the STK15 F31I polymorphism and cancer risk. Divided by ethnicity, 11 case-control studies were focused on Asian subjects and 16 case-control studies focused on Caucasian subjects. After combining all qualified studies, there was statistical evidence of an association between the STK15 F31I polymorphism and increased overall cancer risk in four genetic models: AA vs. TA+TT (OR, 1.18; 95% CI, 1.06–1.31; P=0.002), AA vs. TT (OR, 1.16; 95% CI, 1.01–1.32; P=0.035), AA vs. TA (OR, 1.18; 95% CI, 1.06–1.30; P=0.001), and A vs. T (OR, 1.08; 95% CI, 1.01–1.14; P=0.015) (Table 3, Figure 2). In a stratified analysis by cancer type, there was an increased risk of breast cancer in four genetic models: AA vs. TA+TT (OR, 1.20; 95% CI, 1.05–1.37; P=0.007), AA vs. TT (OR, 1.22; 95% CI, 1.10–1.35; P=0.000), AA vs. TA (OR, 1.19; 95% CI, 1.04–1.36; P=0.011), and A vs. T (OR, 1.08; 95% CI, 1.01–1.15; P=0.017) and of esophageal cancer in two genetic model: AA vs. TA+TT (OR, 1.28; 95% CI, 1.08–1.53; P=0.005) and AA vs. TA (OR, 1.32; 95% CI, 1.10–1.58; P=0.003) (Table 4). In a stratified analysis by ethnicity, significant increases in cancer risk were observed for Asians, but not Caucasians, for four genetic models: AA vs. TA+TT (OR, 1.27; 95% CI, 1.10–1.47; P=0.001), AA vs. TT (OR, 1.26; 95% CI, 1.01–1.56; P=0.039), AA vs. TA (OR, 1.28; 95% CI, 1.12–1.47; P=0.000) and A vs. T (OR, 1.14; 95% CI, 1.02–1.28; P=0.023) (Table 3). In addition, in a stratified analysis by ethnicity in the breast cancer subgroup, significant increases in cancer risk were observed among Asians for two genetic models: AA vs. TA+TT (OR, 1.23; 95% CI, 1.00–1.50; P=0.049) and AA vs. TT (OR, 1.21; 95% CI, 1.01–1.45; P=0.037), as well as among Caucasians in one genetic model: AA vs. TA (OR, 1.14; 95% CI, 1.00–1.29; P=0.042) (Table 5).
Tests for Publication Bias, Sensitivity Analyses, and Heterogeneity
In this meta-analysis, Begg’s Funnel plot and Egger’s test were both conducted to assess publication bias (Figure 3). The shape of funnel plot showed the evidence of funnel plot symmetry in all the genetic model. The results indicated that there were no publication bias for overall cancer in current meta-analysis (A vs. T: Begg’s test P=0.802, Egger’s test P=0.553; AA vs. TT: Begg’s test P=1.000, Egger’s test P=0.938; TA vs. TT: Begg’s test P=0.532, Egger’s test P=0.509; AA+TA vs. TT: Begg’s test P=0.900, Egger’s test P=0.856; AA vs. TT+TA: Begg’s test P=0.739, Egger’s test P=0.784; AA vs. TA: Begg’s test P=0.802, Egger’s test P=0.585).
Sensitivity analyses were conducted to evaluate the influence of each individual dataset on the pooled OR by deleting each particular dataset dropped at a time. The statistical significances of the overall results did not alter when any individual study was omitted, confirming the stability of the results (Figure 4). Trim and fill method was also used to perform sensitivity analyses. The findings showed the results of this meta-analysis were reliable (Figure 5).
The results showed there were large heterogeneities among the studies enrolled. Because tumor origin and ethnicity can influence the results from meta-analyses, we performed subgroup analyses by cancer type and ethnicity (Table 3 and Table 4).The results indicated that esophageal cancer, colorectal cancer, Asian population subgroup may contribute to the heterogeneity. As shown in Table 3, heterogeneity was significant in allele comparison. Galbraith radial plot also was used to analyze the heterogeneity in allele comparison (Figure 6). The results identified eight outliers which might contribute to the major sources of heterogeneity. Further stratified meta-analysis suggested an association of studies published after 2006, conducted in Chinese population and small sample size design (≤1000 subjects) with more prominent heterogeneity (data not shown).
Accumulating evidence suggests environmental factors, genetic components, and gene–environment interactions play important roles in cancer development and progression [37-42]. Recently, a growing interest in the associations between genetic polymorphisms and cancer risk has led to increasing studies on tumor etiology. Many studies have linked tumor development and progression to the amplification and overexpression of STK15 in multiple human cancers (such as breast cancer, colorectal cancer, esophageal cancer, as well as other types of cancer) [43-46]. The STK15 F31I polymorphism has been extensively investigated, and many studies have examined the hypothesis that this polymorphism is relevant to the risk of a variety of cancers; however, the results remain inconclusive and ambiguous. Therefore, we conducted a comprehensive meta-analysis to assess the strength of the association between the STK15 F31I polymorphism and overall cancer risk, and further performed a stratified analysis by ethnicity and cancer type. This meta-analysis, including 27 case-control studies, identified associations between STK15 F31I polymorphism and cancer risk. STK15 F31I polymorphisms (AA vs. TA+TT, AA vs. TT, AA vs. TA, and A vs. T) significantly increased overall cancer risk. In a stratified analysis by cancer type, STK15 F31I polymorphisms (AA vs. TA+TT, AA vs. TT, AA vs. TA, and A vs. T) were also associated with a significant increase in breast cancer risk and esophageal cancer (AA vs. TA+TT and AA vs. TA). In a stratified analysis by ethnicity, the association of STK15 F31I polymorphisms was significant in Asians but not Caucasians.
STK15, also named Aurora A, BTAK, and AIKI, encodes a serine/threonine kinase that acts as a crucial component in spindle formation, the centrosome maturation process, and proper cytokinesis during mitosis. It is located on chromosome 20q13, a region associated with a number of human cancers . These threonine kinases belong to a family of mitotic kinases that maintain chromosomal stability through phosphorylation. Thus, any severe defects in STK15, such as mutations, would lead to drastic genomic instability and trigger apoptosis through cell cycle checkpoint surveillance [19,48]. Consequently, a cell harboring a defective STK15 may lead to cancer . Our results demonstrate a significant statistical impact of STK15 F31I polymorphism on cancer risk. The STK15 F31I polymorphism (T→A), which leads to an amino acid residue substitution at codon 31 phenylalanine (Phe) to isoleucine (Ile), is associated with cellular transformation and dramatically increases chromosomal instability . The STK15 F31I polymorphism (T→A) variant changes the activity of the STK15 box 1, leading to an obstruction in p53 binding and the decreased degradation of STK15 . The stabilized overexpression of STK15 results in centrosome amplification, improper cytokinesis, chromosomal instability, and the promotion of tumorigenesis . In this meta-analysis, our results demonstrate that the T→A change in STK15 may lead to STK15-triggered elevation of cell centrosome proliferation, cell transformation, and dramatically increased chromosomal instability, which may increase the risk of multiple cancers.
Since the outcomes from meta-analysis can be affected by cancer origins, stratified analysis was conducted according to cancer type for the STK15 F31I polymorphism. The results demonstrate that the STK15 F31I polymorphism is associated with an increased risk of breast cancer and esophageal cancer, but not colorectal cancer and other cancers. However, all results should be interpreted with caution. For esophageal cancer, only three case-control studies were recruited in the current meta-analysis, which may restrict statistical power to detect a real influence or generate a fluctuated assessment, large heterogeneities among the studies enrolled in current meta-analysis should also be taken into consideration. More large scale studies are needed to verify these results. Stratified analysis was also performed regarding ethnicity for the STK15 F31I polymorphism. The STK15 F31I polymorphism is associated with the risk of cancer in Asians but not Caucasians. This meta-analysis confirmed the mutual effect of genetic diversity and variants in different populations to the risks of various cancers. In addition, cancer risk was affected by genetic and environmental factors on different levels. The possible reason of the conflicting findings among different ethnicities could be that different genetic backgrounds and environmental factors they exposed to may have disproportionate effects on cancer risk. In the future, further investigations with large sample sizes should be conducted to identify these associations, particularly with regard to gene–gene and gene–environment interactions.
Two significant issues should be addressed in this study, that is, heterogeneity and publication bias, which may influence the results of meta-analysis. We don’t detect a significant publication bias in this meta-analysis, suggesting the reliability of our results. Significant heterogeneity was observed between publications for STK15 F31I polymorphisms. Potential sources of heterogeneity include the publication year, ethnicity, country, cancer type, sample size, and so on. When subgroup analyses were carried out according to ethnicity and cancer type, this heterogeneity was greatly reduced or removed in some subgroups, implying different effects on cancer types and ethnic populations, even for the same polymorphism. And then we performed further subgroup analyses by publication year, country, and sample size. The pooled subgroup analysis of a subset of studies published after 2006, esophageal cancer, Asian population, studies conducted in Chinese population and small sample size, suggested an association with more prominent heterogeneity. The reason might be due to uncontrolled mixed factors, the various susceptibility of cancer in different race or to internal bias in the study design. It is certain that the design of some of the included studies was suboptimal in this meta-analysis. From the forest plot in A vs. T compare genetic model (Figure 2), one can identify that 8 studies are the main sources of heterogeneity [11,21-23,25,27,33,36]. In some publications, the study design included considerable oversights, for example, some investigations used small sample sizes (≤1000 subjects) [22,23,25,27,33,36]. Publication year may be the source of heterogeneity. Some studies published after 2006 was identified with prominent heterogeneity [22,25,27,33,36]. When come to country origins, studies conducted in Chinese population contribute the major outlier [11,21,23,25,27].
The power of this meta-analysis (α=0.05) was evaluated for each single genetic model using an internet-based Power and Sample Size Calculator (PS, version 3.0, 2009, http://biostat.mc.vanderbilt.edu/twiki/bin/view/Main/PowerSampleSize). The power was 1.000 in four genetic models (AA vs. TA+TT, AA vs. TT, AA vs. TA, and A vs. T), 0.526 in AA+TA vs. TT genetic model, and 0.075 in TA vs. TT genetic model.
However, there are certain limitations in this study that should be acknowledged. First, large heterogeneity exists in our meta-analysis, which means the results should be interpreted with caution. Second, all recruited case–control studies were from Asians and Caucasians; thus, our results may only be suitable for these populations. Third, only published studies were eligible in this meta-analysis; therefore, some relevant unpublished studies were inevitably missed, which may lead to bias. Fourth, due to the lack of sufficient and uniform information in original case-control studies, data were not stratified by other factors (e.g., age, smoking, alcohol consumption, and other lifestyle factors). Considering the complexity of cancer etiology and the low penetrance cancer susceptibility gene effects from STK15 F31I SNP, these important environmental factors should not be ignored.
In summary, this meta-analysis suggests the STK15 F31I polymorphism represents a low risk factor for cancer, especially in Asians, in breast cancer and esophageal cancer subgroup. In the future, more studies with large sample sizes should be carried out to clarify the association between STK15 F31I polymorphism and cancer risk, especially for gene–gene and gene–environment interactions.
Conceived and designed the experiments: HG JY. Performed the experiments: WT HQ HD. Analyzed the data: WT HQ HD BS LW HG JY. Contributed reagents/materials/analysis tools: HG JY. Wrote the manuscript: WT HQ HG JY.
- 1. Ihsan R, Chauhan PS, Mishra AK, Yadav DS, Kaushal M et al. (2011) Multiple analytical approaches reveal distinct gene-environment interactions in smokers and non smokers in lung cancer. PLOS ONE 6: e29431. doi:10.1371/journal.pone.0029431.
- 2. Liu L, Wu C, Wang Y, Zhong R, Wang F et al. (2011) Association of candidate genetic variations with gastric cardia adenocarcinoma in Chinese population: a multiple interaction analysis. Carcinogenesis 32: 336-342. doi:10.1093/carcin/bgq264.
- 3. Andrew AS, Nelson HH, Kelsey KT, Moore JH, Meng AC et al. (2006) Concordance of multiple analytical approaches demonstrates a complex relationship between DNA repair gene SNPs, smoking and bladder cancer susceptibility. Carcinogenesis 27: 1030-1037. doi:10.1093/carcin/bgi284.
- 4. Maser RS, DePinho RA (2002) Connecting chromosomes. Crisis --Cancer. Science 297: 565-569.
- 5. Lengauer C, Kinzler KW, Vogelstein B (1998) Genetic instabilities in human cancers. Nature 396: 643-649. doi:10.1038/25292.
- 6. Gu J, Gong Y, Huang M, Lu C, Spitz MR et al. (2007) Polymorphisms of STK15 (Aurora-A) gene and lung cancer risk in Caucasians. Carcinogenesis 28: 350-355.
- 7. Ewart-Toland A, Briassouli P, de Koning JP, Mao JH, Yuan J et al. (2003) Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat Genet 34: 403-412. doi:10.1038/ng1220. PubMed: 12881723.
- 8. Egan KM, Newcomb PA, Ambrosone CB, Trentham-Dietz A, Titus-Ernstoff L et al. (2004) STK15 polymorphism and breast cancer risk in a population-based study. Carcinogenesis 25: 2149-2153. doi:10.1093/carcin/bgh231.
- 9. Ruan Y, Song AP, Wang H, Xie YT, Han JY et al. (2011) Genetic polymorphisms in AURKA and BRCA1 are associated with breast cancer susceptibility in a Chinese Han population. J Pathol 225: 535-543. doi:10.1002/path.2902.
- 10. Webb EL, Rudd MF, Houlston RS (2006) Case-control, kin-cohort and meta-analyses provide no support for STK15 F31I as a low penetrance colorectal cancer allele. Br J Cancer 95: 1047-1049. doi:10.1038/sj.bjc.6603382.
- 11. Miao X, Sun T, Wang Y, Zhang X, Tan W et al. (2004) Functional STK15 Phe31Ile polymorphism is associated with the occurrence and advanced disease status of esophageal squamous cell carcinoma. Cancer Res 64: 2680-2683. doi:10.1158/0008-5472.CAN-04-0651.
- 12. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151: 264-269, W264.
- 13. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560. doi:10.1136/bmj.327.7414.557.
- 14. MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk (2010) Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women. Breast Cancer Res Treat 120: 727-736.
- 15. Vidarsdottir L, Bodvarsdottir SK, Hilmarsdottir H, Tryggvadottir L, Eyfjord JE (2007) Breast cancer risk associated with AURKA 91T -->A polymorphism in relation to BRCA mutations. Cancer Lett 250: 206-212. doi:10.1016/j.canlet.2006.10.003.
- 16. Tchatchou S, Wirtenberger M, Hemminki K, Sutter C, Meindl A et al. (2007) Aurora kinases A and B and familial breast cancer risk. Cancer Lett 247: 266-272. doi:10.1016/j.canlet.2006.05.002. PubMed: 16762494.
- 17. Fletcher O, Johnson N, Palles C, dos Santos Silva I, McCormack V et al. (2006) Inconsistent association between the STK15 F31I genetic polymorphism and breast cancer risk. J Natl Cancer Inst 98: 1014-1018. doi:10.1093/jnci/djj268.
- 18. Cox DG, Hankinson SE, Hunter DJ (2006) Polymorphisms of the AURKA (STK15/Aurora Kinase) Gene and Breast Cancer Risk (United States). Cancer Causes Control 17: 81-83. doi:10.1007/s10552-005-0429-9.
- 19. Lo YL, Yu JC, Chen ST, Yang HC, Fann CS et al. (2005) Breast cancer risk associated with genotypic polymorphism of the mitosis-regulating gene Aurora-A/STK15/BTAK. Int J Cancer 115: 276-283. doi:10.1002/ijc.20855. PubMed: 15688402.
- 20. Dai Q, Cai QY, Shu XO, Ewart-Toland A, Wen WQ et al. (2004) Synergistic effects of STK15 gene polymorphisms and endogenous estrogen exposure in the risk of breast cancer. Cancer Epidemiol Biomarkers Prev 13: 2065-2070. PubMed: 15598762.
- 21. Sun T, Miao X, Wang J, Tan W, Zhou Y et al. (2004) Functional Phe31Ile polymorphism in Aurora A and risk of breast carcinoma. Carcinogenesis 25: 2225-2230. doi:10.1093/carcin/bgh244.
- 22. Chen J, Sen S, Amos CI, Wei C, Jones JS et al. (2007) Association between Aurora-A kinase polymorphisms and age of onset of hereditary nonpolyposis colorectal cancer in a Caucasian population. Mol Carcinog 46: 249-256. doi:10.1002/mc.20283.
- 23. Zhang WJ, Miao XP, Sun T, Zhang XM, Qu SN et al. (2006) Association between genetic polymorphism in STK15 and risk of colorectal cancer in a Chinese population. Zhonghua Zhong Liu Za Zhi 28: 43-46.
- 24. Hienonen T, Salovaara R, Mecklin JP, Jarvinen H, Karhu A et al. (2006) Preferential amplification of AURKA 91A (Ile31) in familial colorectal cancers. Int J Cancer 118: 505-508. doi:10.1002/ijc.21344.
- 25. Chen XB, Chen GL, Liu JN, Yang JZ, Yu DK et al. (2009) Genetic polymorphisms in STK15 and MMP-2 associated susceptibility to esophageal cancer in Mongolian population. Zhonghua Yu Fang Yi Xue Za Zhi 43: 559-564.
- 26. Sang Y, Gu H, Ding G, Yang W, Chen S et al. (2012) Association between the esophageal cancer susceptibility and the STK15 T+91A polymorphism. Chinese Journal Experimental Surgery 29: 1220.
- 27. Song B, Hao G, Ma W, Tian Y, Du L (2010) Association between STK15 genetic polymorphism and risk of bladder cancer. Xiandai Miniao Wa ike Za Zhi 15: 277-279.
- 28. Ju H, Cho H, Kim YS, Kim WH, Ihm C et al. (2006) Functional polymorphism 57Val>Ile of aurora kinase A associated with increased risk of gastric cancer progression. Cancer Lett 242: 273-279. doi:10.1016/j.canlet.2005.11.015.
- 29. Chen L (2005) Genetic polymorphisms and disease risks: STKl5 gene and risk for gastric cancer, MMP9 gene and risk for Thoracic Aortic Aneurysm and Thoracic Aortic Dissection. China Medical University. 101 p.
- 30. Dogan I, Ekmekci A, Yurdakul AS, Onen IH, Ozturk C et al. (2008) Polymorphisms in the aurora-A gene is not associated with lung cancer in the Turkish population. DNA Cell Biol 27: 443-448. doi:10.1089/dna.2007.0719.
- 31. Wang W, Spitz MR, Yang H, Lu C, Stewart DJ et al. (2007) Genetic variants in cell cycle control pathway confer susceptibility to lung cancer. Clin Cancer Res 13: 5974-5981. doi:10.1158/1078-0432.CCR-07-0113. PubMed: 17908995.
- 32. Ricketts C, Zeegers MP, Lubinski J, Maher ER (2009) Analysis of germline variants in CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF in familial and sporadic renal cell carcinoma. PLOS ONE 4: e6037. doi:10.1371/journal.pone.0006037.
- 33. Hammerschmied CG, Stoehr R, Walter B, Wieland WF, Hartmann A et al. (2007) Role of the STK15 Phe31Ile polymorphism in renal cell carcinoma. Oncol Rep 17: 3-7.
- 34. Dicioccio RA, Song H, Waterfall C, Kimura MT, Nagase H et al. (2004) STK15 polymorphisms and association with risk of invasive ovarian cancer. Cancer Epidemiol Biomarkers Prev 13: 1589-1594.
- 35. Navaratne KS, Weil RJ (2010) The Aurora A F31I polymorphism is not a risk factor for glioblastoma. World Neurosurg 74: 144-146. doi:10.1016/j.wneu.2010.04.003.
- 36. Akkiz H, Bayram S, Bekar A, Akgollu E, Ozdil B (2010) Relationship between functional polymorphism in the Aurora A gene and susceptibility of hepatocellular carcinoma. J Viral Hepat 17: 668-674.
- 37. Terry PD, Umbach DM, Taylor JA (2006) APE1 genotype and risk of bladder cancer: evidence for effect modification by smoking. Int J Cancer 118: 3170-3173. doi:10.1002/ijc.21768.
- 38. Zhao G, Li C, Okoro CA, Li J, Wen XJ, et al. (2013) Trends in modifiable lifestyle-related risk factors following diagnosis in breast cancer survivors. J Cancer Surviv.
- 39. Touvier M, Druesne-Pecollo N, Kesse-Guyot E, Andreeva VA, Galan P et al. (2013) Demographic, socioeconomic, disease history, dietary and lifestyle cancer risk factors associated with alcohol consumption. Int J Cancer.
- 40. Nickels S, Truong T, Hein R, Stevens K, Buck K et al. (2013) Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors. PLOS Genet 9: e1003284.
- 41. Siegert S, Hampe J, Schafmayer C, von Schonfels W, Egberts JH et al. (2013) Genome-wide investigation of gene-environment interactions in colorectal cancer. Hum Genet 132: 219-231. doi:10.1007/s00439-012-1239-2.
- 42. Shi Y, Luo GJ, Zhang L, Shi J, Zhang DQ et al. (2012) Interaction between alcohol consumption and CYP 2C19 gene polymorphism in relation to oesophageal squamous cell carcinoma. PLOS ONE 7: e43412. doi:10.1371/journal.pone.0043412.
- 43. Wang X, Zhou YX, Qiao W, Tominaga Y, Ouchi M et al. (2006) Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation. Oncogene 25: 7148-7158. doi:10.1038/sj.onc.1209707.
- 44. Briassouli P, Chan F, Savage K, Reis-Filho JS, Linardopoulos S (2007) Aurora-A regulation of nuclear factor-kappaB signaling by phosphorylation of IkappaBalpha. Cancer Res 67: 1689-1695. doi:10.1158/0008-5472.CAN-06-2272.
- 45. Baba Y, Nosho K, Shima K, Irahara N, Kure S et al. (2009) Aurora-A expression is independently associated with chromosomal instability in colorectal cancer. Neoplasia 11: 418-425.
- 46. Yang SB, Zhou XB, Zhu HX, Quan LP, Bai JF et al. (2007) Amplification and overexpression of Aurora-A in esophageal squamous cell carcinoma. Oncol Rep 17: 1083-1088. PubMed: 17390048.
- 47. Evans WE, Relling MV (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286: 487-491. doi:10.1126/science.286.5439.487.
- 48. Marumoto T, Zhang D, Saya H (2005) Aurora-A - a guardian of poles. Nat Rev Cancer 5: 42-50. doi:10.1038/nrc1526. PubMed: 15630414.
- 49. Chen J, Li D, Wei C, Sen S, Killary AM et al. (2007) Aurora-A and p16 polymorphisms contribute to an earlier age at diagnosis of pancreatic cancer in Caucasians. Clin Cancer Res 13: 3100-3104. doi:10.1158/1078-0432.CCR-06-2319.